Faithward Advisors’s Genmab GMAB Stock Holding History

Faithward Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,350	Closed	-$368K	–	253
2022 Q2	$368K	Sell	11,350 -3,019	-21%	-$97.8K	0.08%	104
2022 Q1	$519K	Sell	14,369 -1,463	-9%	-$50.2K	0.1%	95
2021 Q4	$626K	Sell	15,832 -11,258	-42%	-$469K	0.12%	87
2021 Q3	$1.18M	Sell	27,090 -5,990	-18%	-$269K	0.23%	64
2021 Q2	$1.35M	Sell	33,080 -50,334	-60%	-$1.94M	0.27%	55
2021 Q1	$2.74M	Buy	+83,414	New	+$3.14M	0.61%	45
2020 Q4	–	Sell	-97,012	Closed	-$3.55M	–	150
2020 Q3	$3.55M	Sell	97,012 -123	-0.1%	-$4.45K	0.86%	42
2020 Q2	$3.29M	Buy	+97,135	New	+$2.65M	0.85%	41

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Faithward Advisors's GMAB Position: Q3 2022 in Review

Faithward Advisors sold out of Genmab (GMAB) in Q3 2022, closing a stake of 11,350 shares — an estimated $368K sold.

Faithward Advisors first reported a position in GMAB in Q2 2020 and held it in 8 quarters. The position peaked at $3.55M in Q3 2020. 193 funds tracked by Wall St. Rank hold GMAB as of Q3 2022.

Faithward Advisors reported no remaining Genmab position as of Q3 2022 after selling out during the quarter.
Faithward Advisors sold 11,350 Genmab shares in Q3 2022, an estimated $368K.
Faithward Advisors first reported a position in Genmab in Q2 2020 and held it in 8 quarters.
Faithward Advisors's Genmab position peaked at $3.55M in Q3 2020.
193 funds tracked by Wall St. Rank held Genmab as of Q3 2022.

Based on Faithward Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.